Short-cycle therapy in adolescents after continuous therapy with established viral suppression: The impact on viral load suppression

AIDS Research and Human Retroviruses

Volumn 25, Issue 6, 2009, Pages 555-561

  Rudy, Bret J ^a,g   Sleasman, John ^b   Kapogiannis, Bill ^c   Wilson, Craig M ^d   Bethel, James ^e   Serchuck, Leslie ^c   Ahmad, Sushma ^e   Cunningham, Coleen K ^f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e WESTAT   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENCE; ADOLESCENT; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG WITHDRAWAL; EVALUATION; FEMALE; HIGH RISK BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT COMPLIANCE; PERINATAL PERIOD; PRIORITY JOURNAL; SHORT COURSE THERAPY; SIDE EFFECT; TREATMENT DURATION; VIRUS INHIBITION; VIRUS LOAD; VIRUS TRANSMISSION; METHODOLOGY; MULTICENTER STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 85047683140     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0203     Document Type: Article

References (26)

1. Pallela FJ, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med1998;338:853-860.
2. World Health Organization: Preventing HIV/AIDS in young people: a systematic review of the evidence from developing countries. In: WHO Technical Report Series (Ross D, Dick B, and Ferguson J, eds.). World Health Organization, Geneva, 2006.
3. Flynn P, Rudy B, Douglas S, et al.: Virologic and immuno-logic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis 2004;190:271-279.
4. Rudy B, Lindsey J, Flynn P, et al.: Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: Week 60 results from the PACTG 381 cohort. AIDS Res Hum Retro-viruses 2006;22:213-221.
5. Flynn P, Rudy B, Lindsey J, et al.: Long-term observation of adolescents initiating HAART therapy: Three-year follow-up. AIDS Res Hum Retroviruses 2007;22:213-221.
6. Pai NP, Tulsky JP, Lawrence J, Colford JM Jr, and Reingold AL: Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev 2005;4:CD005482.
7. Pai NP, Lawrence J, Reingold AL, and Tulsky JP: Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. Cochrane Database Syst Rev 2006;3: CD006148.
8. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296.
9. Lawrence J, Hullsiek KH, Thackeray LM, et al.: Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: Final results of the CPCRA 064 study. J Acquir Immune Defic Syndr 2006;43: 169-178.
10. Papasavvas E, Kostman JR, Mounzer K, et al.: Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 2004;1:e64.
11. Danel C, Moh R, Minga A, et al.: CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): A randomised trial. Lancet 2006;367:1981-1989.
12. Lawrence J, Mayers DL, Hullsiek KH, et al.: Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003;349:837-846.
13. Walmsley SL, Thorne A, Loutfy MR, et al.: A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active anti-retroviral therapy (Canadian HIV Trials Network Study 164). J Acquir Immune Defic Syndr 2007;45:418-425.
14. Dybul M, Chun TW, Yoder C, et al.: Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immuno-logic, and toxicity parameters. Proc Natl Acad Sci USA 2001;98:15161-15166.
15. Ananworanich J, Siangphoe U, Hill A, et al.: Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: The HIV Netherlands Australia Thailand Research Collaboration 001.4 study. J Acquir Immune Defic Syndr 2005;39:523-529.
16. Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, and Morse GD: Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials 2007;8:19-23.
17. Dybul M, Nies-Kraske E, Dewar R, et al.: A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efa-virenz for the treatment of chronic HIV infection. J Infect Dis 2004;189:1974-1982.
18. Cardiello PG, Hassink E, Ananworanich J, et al.: A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005;40:594-600.
19. Staprans S, Hamilton B, Follansbee S, et al.: Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995;182:1727-1737.
20. Nettles R, Kieffer T, Kwon P, et al.: Intermittent HIV-1 vi-remia (Blips) and drug resistance in patients receiving HAART. JAMA 2005;293:817-829.
21. Casseb J and Da Silva Duarte AJ: Structured intermittent therapy with seven-day cycles of HAART for chronic HIV infection: A pilot study in São Paulo, Brazil. AIDS Patient Care STDS 2005;19:425-428.
22. Murphy D, Belzer M, Durako S, et al.: Longitudinal anti-retroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med 2005;159:764-770.
23. Arnedo-Valero M, Garcia F, Gil C, et al.: Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. Clin Infect Dis 2005;41:883-890.
24. Wang YM, Dyer WB, Workman C, et al.: Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART. Curr HIV Res 2007;5:235-250.
25. Nuesch R, Ananworanich J, Sirivichayakul S, et al.: Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis 2005;40:728-734.
26. Reynolds SJ, Kityo C, Ssali F, et al: A randomized, controlled, non-inferiority trial of two short cycle intermittent regimens compared with continuous antiretroviral therapy for the treatment of chronic HIV infection in Uganda. ICCAA/ IDSA. 2008; abstract H-1250.